These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 15555739

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. New oral delivery systems for treatment of inflammatory bowel disease.
    Friend DR.
    Adv Drug Deliv Rev; 2005 Jan 06; 57(2):247-65. PubMed ID: 15555741
    [Abstract] [Full Text] [Related]

  • 4. Antioxidants and mucosa protectives: realistic therapeutic options in inflammatory bowel disease?
    Kruidenier L, Verspaget HW.
    Mediators Inflamm; 1998 Jan 06; 7(3):157-62. PubMed ID: 9705602
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Role of heat shock proteins (molecular chaperones) in intestinal mucosal protection.
    Otaka M, Odashima M, Watanabe S.
    Biochem Biophys Res Commun; 2006 Sep 15; 348(1):1-5. PubMed ID: 16875664
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.
    Kanai T, Nemoto Y, Kamada N, Totsuka T, Hisamatsu T, Watanabe M, Hibi T.
    Curr Opin Gastroenterol; 2009 Jul 15; 25(4):306-13. PubMed ID: 19448533
    [Abstract] [Full Text] [Related]

  • 10. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease.
    Shanahan F.
    Am J Physiol Gastrointest Liver Physiol; 2005 Mar 15; 288(3):G417-21. PubMed ID: 15701620
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa.
    Collnot EM, Ali H, Lehr CM.
    J Control Release; 2012 Jul 20; 161(2):235-46. PubMed ID: 22306429
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease.
    Mitsuyama K, Sata M.
    Expert Opin Ther Targets; 2008 Mar 20; 12(3):301-12. PubMed ID: 18269340
    [Abstract] [Full Text] [Related]

  • 20. Epithelial tight junctions in intestinal inflammation.
    Schulzke JD, Ploeger S, Amasheh M, Fromm A, Zeissig S, Troeger H, Richter J, Bojarski C, Schumann M, Fromm M.
    Ann N Y Acad Sci; 2009 May 20; 1165():294-300. PubMed ID: 19538319
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.